Vlad Coric, Biohaven CEO
March 22, 2023 11:20 AM EDT
Deals

Bio­haven grabs TYK2/JAK1 drug for $20M to start, $950M on the line — to go af­ter Parkin­son's

Paul Schloesser

Associate Editor

Bio­haven is bet­ting big on tar­get­ing brain dis­or­ders such as Parkin­son’s and po­ten­tial­ly Alzheimer’s.

The Con­necti­cut biotech an­nounced Wednes­day that it …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times